Study finds Novo's tablet for vaginal atrophy increases compliance compared to creams

A study found that tablets increase compliance among postmenopausal women suffering from vaginal atrophy when compared to cream. Almost 90% of patients who took the cream stopped using it after the first prescription, compared to 58% of patients who were on Novo Nordisk's ($NVO) Vagifem 10 milligram estradiol tablets. The study was based on insurance claims data on more than 30,000 women. More from Medscape (reg. req.) | Abstract